Skip to main content
. 2016 Sep 21;5(9):e104. doi: 10.1038/emi.2016.101

Table 1. Patient characteristics and symptoms/clinical signs.

  Total (n=312) HFMD (n=142) Central nervous system involvement (n=20) Cardiopulmonary failure (n=150)
Age (years)
 Mean (95% CI) 2.51 2.18a (1.78–2.58) 2.51 (1.04–4.03) 2.84b (2.28–3.40)
 Median 2 2 1.7 2
 Min.–max. 0.16–27 0.75–27 0.91–14 0.16–27
         
Sex (% female) 134 (42.8%) 52 (36.6%) 8 (40.0%) 74c (50.3%)
         
Hospitalization
 Nod 62 (20.0%) 62 (43.4%) 0 0
 Hospitalized 250 (80.0%) 80 (56.6%) 20 (100%) 150 (100%)
         
Clinical symptoms
 Papulovesicular rash 130 (42.4%) 103 (72.0%) 5 (35.7%) 22 (14.7%)
 Fatal cases 98 (31.4%) 0 3 (15.0%) 95 (63.3%)
         
Laboratory diagnostic tests (RT-PCR and/or virus isolation)
 EV-A71 208 (66.6%) 96 (67.6%) 11 (55.0%) 101 (67.3%)
 Other than EV-A71 32 (10.3%) 18 (12.7%) 5 (25.0%) 9 (6.0%)
  Subtyped 27 (73%) 15 5 7
  Unsubtypable 5 (13.5%) 3 0 2
 Co-infection with EV-A71 and non-EV-A71 5 (1.6%) 1 (0.7%) 0 4 (2.7%)
 Negative 67 (21.5%) 27 (19.0%) 4 (20.0%) 36 (24.0%)
         
Sequencing
 EV-A71        
  VP1 9 3 (33.3%) 4 (44.5%) 2 (22.2%)
  Full genome 11 4 (36.5%) 2 (18.0%) 5 (45.5%)
 Other than EV-A71        
  VP1 32 16 (50.0%) 5 (15.6%) 11 (35.4%)
  Enterovirus A 18 (56.3%) 14 CV-A6, 1 CV-A16   2 CV-A6, 1 CV-A16
  Enterovirus B 7 (21.9%) 0 2 CV-B3, 1 E-2 and 1 EV-B80 1 EV-B83, 1 CV-B2, 1 E-31 and 1 CV-A9
  Enterovirus C 2 (6.3%) 0 1 CV-A20 1 EV-C116
  Co-infection with EV-A71 5 (15.5%) 1 CV-A6 (A) 0 2 CV-B2 (B), 1 EV-C96 (C) and 1 PV-3 (C)

Abbreviations: enterovirus A, (A); enterovirus B, (B); enterovirus C, (C); confidence interval, CI; coxsackievirus A, CVA; coxsackievirus B, CVB; echovirus, E; enterovirus, EV; human enterovirus 71, EV-A71; hand, foot and mouth disease, HFMD; poliovirus, P; reverse transcription PCR, RT-PCR; poliovirus E vaccine-related, VRPV.

a

n=141.

b

n=146.

c

n=147.

d

Patients recruited at the outpatient department.